Cartesian Therapeutics is abiotechnology company structured around immunotherapy. Originally developed by NIH researchers, the firm's proprietary technology, has the potential to greatly broaden the use of Chimeric Antigen Receptor (CAR) cells for patients with multiple myeloma and other diseases. Although treatment has improved significantly in the past two decades, nearly all patients eventually relapse, and the disease remains incurable. Chimeric antigen receptor (CAR) therapies are the primary focus of Cartesian personnel; and the firm's lead product: Descartes-08,
